MELBOURNE, FL, April 29, 2026 /24-7PressRelease/ -- AWilliam Miller has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

An accomplished expert of more than 15 years in operational management, Mr. Miller currently serves as the chief executive officer at Hythlayn Inc. — which he founded in 2024 — where he and his team have made advancements in water soluble compounds and sell their technology to select supplement manufacturers. Drawing on his extensive experience in pharmaceutical innovation and executive management, he oversees the strategic direction and operational leadership throughout the company.

Since 2020, Mr. Miller has also held the role of chief executive officer at Villya Pharmaceuticals in Melbourne, Florida, where his tenure has been marked by significant achievements in drug development and intellectual property. His personal battle with the blood fluke parasite schistosomiasis, which lasted for eight years, has profoundly influenced his career path. After being cured with Praziquantel — a drug developed by Merck and Bayer — he discovered that the standard treatment was ineffective for his wife's advanced case of female genital schistosomiasis.

Refusing to accept defeat after many medical professionals had exhausted their options, Mr. Miller converted a spa room into a laboratory where he developed a new medicine that ultimately cured her condition. This innovation — his proudest personal and professional achievement — led to their first pharmaceutical patent and spurred further research into more palatable formulations of Praziquantel for children, who often reject the bitter tablet form.

Under Mr. Miller's leadership, Villya Pharmaceuticals has secured additional patents, including those for compositions and methods for improving the solubility of erectile dysfunction therapeutics and formulations of Praziquantel. Passionate about raising awareness of these conditions and their treatments worldwide, he has contributed to significant advancements in drug bioavailability and pediatric medicine.

From 2018 to 2024, Mr. Miller served as president of S7 LLC, a medical sales entity that specializes in rapid antigen and antibody tests. During this period, he guided the organization through various business ventures and strategic initiatives, further honing his expertise in management and organizational leadership. Additionally, he was president of ICT International from 2018 to 2022, during which he managed manufacturing projects and expanded the company's global reach in testing for tropical and infectious diseases.

Earlier in his career, Mr. Miller worked as a crew chief for the United States Department of State from 2007 to 2018. His responsibilities included overseeing contract operations in challenging environments such as Iraq and other locations worldwide. It was during this time that he initially contracted schistosomiasis — a pivotal event that would shape his subsequent professional trajectory and advocacy efforts.

Mr. Miller's academic background includes coursework at Indiana State University, which provided a strong foundation for his scientific research and entrepreneurial pursuits. Reflecting on his journey thus far, he attributes much of his success to overcoming adversity and maintaining a relentless work ethic, crediting the challenges he faced with motivating him to persist where others might have given up.

Mr. Miller's commitment to advancing treatments for neglected diseases led him to collaborate with Rush University in Chicago and the University of Edmonton in Canada on further studies related to drug solubility and bioavailability. The Massachusetts Institute of Technology chemistry department later verified his method for transforming insoluble drugs into soluble forms — an advancement that improved pharmaceutical usability and resulted in additional patents.

Beyond his professional roles, Mr. Miller is a dedicated member of the Freemasons, reflecting his commitment to ethical leadership and community service. He also founded the online publication Schistosomiasis.org Inc. in 2021 to raise awareness about this neglected tropical disease, advocate for improved treatments globally and provide critical insights for individuals and families seeking knowledge about the condition. An equally dedicated family man, he enjoys traveling, going to the beach, hiking and spending quality time with his wife and children as a balance to his vocational endeavors.

Determined to further his impact in the coming years, Mr. Miller aims to see all the intellectual property products developed under his guidance displayed on shelves worldwide. He remains focused on translating successful preclinical results into human applications, securing licensing agreements and bringing innovative treatments to market for those most in need. His past achievements and future goals alike reflect a legacy of resilience, outstanding leadership and devotion to helping others through everything he does.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. The suite of Marquis® publications, including Who's Who in America® and Who's Who in the World®, remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the globe. Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #